TGFB1 and neoplasm: Targeting key immunosuppressive factors in TIME such as TGF-β1 and chemokine receptors CXCR1/2 through pharmacological antagonists represent some of the strategies to block the immunosuppressive milieu, leading to tumor growth and the nonsuccess of immunotherapies.